Raymond James Financial
ATXS

Raymond James Financial’s Astria Therapeutics ATXS Stock Holding History

Raymond James Financial’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-96,020
Closed -$699K – 5171
2025
Q3 		$699K Buy
96,020
+5,437
+6% +$36.8K ﹤0.01% 3916
2025
Q2 		$486K Buy
90,583
+12,174
+16% +$59K ﹤0.01% 4026
2025
Q1 		$419K Sell
78,409
-635
-0.8% -$4.44K ﹤0.01% 4040
2024
Q4 		$707K Buy
+79,044
New +$840K ﹤0.01% 3683

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's ATXS Position: Q4 2025 in Review

Raymond James Financial sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 96,020 shares — an estimated $699K sold.

Raymond James Financial first reported a position in ATXS in Q4 2024 and held it in 4 quarters. The position peaked at $707K in Q4 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Raymond James Financial reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Raymond James Financial sold 96,020 Astria Therapeutics shares in Q4 2025, an estimated $699K.
  • Raymond James Financial first reported a position in Astria Therapeutics in Q4 2024 and held it in 4 quarters.
  • Raymond James Financial's Astria Therapeutics position peaked at $707K in Q4 2024.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Raymond James Financial's 13F filing for Q4 2025, filed 18 Feb 2026.